文献速递骨显像与常规 SPECT肿瘤 PET/CT

18F-FDG PET/CT在关节结核抗结核化疗疗效评估及治疗终点判定中的作用:一项初步研究

Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints: A Pilot Study.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该前瞻性初步研究纳入40例关节结核患者,在抗结核治疗基线及约6、12、18个月时行临床、生化及18F-FDG PET/CT评估,37例随访至完全缓解。结果显示PET/CT视觉与定量指标随治疗显著下降,首次随访MV降幅≤71%可预测需延长治疗超过12个月,第二次随访MV≤12.67 mL预测完全缓解并在第三次随访验证准确率84.4%。

要点

  • 18F-FDG PET/CT可评估关节结核总疾病负荷并监测抗结核治疗反应。
  • 首次随访MV降幅≤71%预测需延长ATT超过12个月(敏感度80.8%,特异度81.8%)。
  • 第二次随访MV≤12.67 mL预测完全缓解,第三次随访验证准确率84.4%。

核心结论

  • 18F-FDG PET/CT是评估关节结核总疾病负荷、抗结核治疗反应及判定治疗终点的优秀工具。

研究设计与样本

  • 前瞻性初步研究纳入40例临床、影像及组织病理学证实的关节结核患者(平均年龄35.3岁,27例男性),在基线及ATT约6、12、18个月时行临床、生化及PET/CT评估;2例失访、1例放弃治疗,37例随访至完全缓解。

主要发现

  • 膝关节(n=18)和踝关节(n=7)为最常见受累部位,基线中位MV为85.10 mL、中位SUVmax比值为7.21。
  • 5例合并不相邻椎体受累,12例有肺部病灶,2例有脓肿,6例有纵隔淋巴结受累,30例有局部淋巴结受累。
  • ATT 6、12、18个月后分别有1/39、11/37、30/37例达到完全缓解。
  • 每次随访视觉模拟评分、压痛、关节肿胀、SUVmax比值及MV均显著下降(Friedman检验,P<0.001)。
  • 骨骼病灶中位达CR时间显著长于骨外病灶(591 vs 409天;Wilcoxon符号秩检验,P<0.001)。

关键数值与推荐

  • 首次随访MV降幅≤71%预测需延长ATT超过12个月,敏感度80.8%、特异度81.8%。
  • 第二次随访ROC分析得出MV≤12.67 mL预测完全缓解,第三次随访验证准确率84.4%。
  • 关节病灶达CR时间与首次随访MV正相关(Pearson=0.452,P=0.005),与MV较基线的百分比变化负相关(Pearson=-0.620,P<0.001)。

临床怎么用

  • 可在ATT期间系列行18F-FDG PET/CT定量评估MV与SUVmax比值,辅助判断疗效与治疗终点。
  • 首次随访MV降幅≤71%提示可能需要延长ATT超过12个月,可据此个体化调整疗程。
  • PET/CT达完全缓解者在中位271天随访中维持无病状态,支持其作为停药参考。

局限性

  • 本研究为初步研究,样本量有限(40例纳入、37例完成随访),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to explore the utility of 18F-FDG PET/CT in the assessment of response to antitubercular treatment (ATT) and identification of treatment endpoint. PATIENTS AND METHODS: Forty patients (mean age, 35.3 years; 27 men) with clinically, radiologically, and histopathologically proven joint tuberculosis prospectively underwent clinical, biochemical, and PET/CT evaluation at baseline and after ~6, 12, and 18 months of ATT. Two patients were lost to follow-up, and 1 defaulted treatment. The remaining 37 were followed up until complete response (CR) was achieved. Images were visually and quantitatively (SUVmax ratio and metabolically active disease volume [MV]) evaluated by 2 experienced nuclear medicine physicians. RESULTS: Knee (n = 18) and ankle (n = 7) were the most frequently involved sites. The median MV and SUVmax ratio at baseline were 85.10 mL and 7.21, respectively. Five patients had noncontiguous vertebral involvement, 12 had pulmonary lesions, 2 had abscesses, 6 had mediastinal, and 30 had local lymph nodal involvement. Complete response was seen in 1/39, 11/37, and 30/37 patients after 6, 12, and 18 months of ATT. Significant reductions in visual analog scale score, tenderness, joint swelling, SUVmax ratios, and MVs (Friedman test, P < 0.001) were seen after each follow-up. The median time-to-CR in skeletal lesions was significantly longer than extraskeletal lesions (591 vs 409 days; Wilcoxon signed-rank test, P < 0.001). Time-to-CR in joint lesions positively correlated with MV at first follow-up (Pearson = 0.452, P = 0.005) and negatively correlated with percentage change in MV (first follow-up from baseline) (Pearson = -0.620, P < 0.001). ROC analysis yielded a cutoff of ≤71% reduction in MV at first follow-up (80.8% sensitivity, 81.8% specificity) to predict extension of ATT beyond 12 months. Using ROC analysis at second follow-up, a cutoff of ≤12.67 mL (for CR) was derived and was validated in patients at the third follow-up, with an accuracy of 84.4%. Patients with CR in PET/CT maintained disease-free state during a mean follow-up of 271 days. CONCLUSIONS: 18F-FDG PET/CT is an excellent tool in estimating total disease burden, assessing response to ATT and identification of treatment endpoint in joint tuberculosis.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Goyal D, Shriwastav R, Mittal R, et al. Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints: A Pilot Study. Clin Nucl Med. 2021. PMID: 33512950. doi:10.1097/RLU.0000000000003518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。